Proactive Investors - Run By Investors For Investors

Scancell strengthens IP with two “important” patent grants in US and Europe

The US patent covers Modi-1, while the European patent relates to a monoclonal antibody called FG88
test tubes in laboratory
Scancell is developing drugs that harness the body’s immune system to attack cancers

Scancell Holdings PLC (LON:SCLP) has strengthened its intellectual property (IP) after it was granted two “important” patents in the US and Europe.

The US patent covers Modi-1 – the first clinical candidate from Scancell’s Moditope immunotherapy platform.

It claims methods of stimulating an immune response to a tumour and methods of treating cancer using peptides of Modi-1.

READ: Scancell lauds another six months of progress

Similar protection has already been granted in Europe, South Africa, and Australia, as well as acceptance for grant in China.

As for the European patent announced today, that relates to FG88, a monoclonal antibody directed to tumour associated glycans, which Scancell said further strengthens the commercial positioning of its monoclonal antibody development programme.

“We are pleased to have been granted these two important patents for our immunotherapy platforms in the United States and Europe,” said chief executive Cliff Holloway.

“This Moditope patent provides protection for Modi-1 in the US and further endorses the novelty of Scancell's work in identifying a new class of cancer vaccine.”

He added: “Through the continued expansion of our intellectual property portfolio in the US and Europe, we believe we are well positioned to advance our pipeline of novel immunotherapies.”

View full SCLP profile View Profile

Scancell Holdings PLC Timeline

Related Articles

test tubes
April 16 2019
Summit Therapeutics' potential breakthrough targets C.difficile
seeds in a bowl
March 07 2019
The Vancouver company is developing Omega-3 products as oil, powder or emulsion to be used as food additives
Scientists in a lab
January 31 2019
CEO Gary Phillips says Pharmaxis’ healthy cash balance gives it time to choose between in-house and partnering options.

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use